The Tenaya Therapeutics team (Tenaya Therapeutics)
With another $106 million in the bank, heart-focused Tenaya Therapeutics is ready to talk targets. The series C funding will propel several preclinical programs toward the clinic, including a gene therapy for hypertrophic cardiomyopathy (HCM), as well as set up a site in the Bay Area to manufacture vectors to deliver its treatments.
The South San Francisco-based biotech is attacking heart disease through three different angles: gene therapy, cellular regeneration and precision medicine. It’s taking this multipronged approach so it can solve the different types of problems that can lead to heart disease and heart failure.
China startup Suzhou Medilink Therapeutics nabs $50M for hot R&D cancer field fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.